You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


NICE does not recommend tucatinib for advanced breast cancer

NICE has published draft guidance for public consultation which does not recommed tucatinib, in combination with trastuzumab and capecitabine, for some types of breast cancer.